Explanation of the mechanism of carcinogenesis and syntheses of anticancer agents with high selectivity

Science in China, Series B: Chemistry

Volumn 49, Issue 1, 2006, Pages 44-62

  Dai, Qianhuan ^a,b  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Anticancer platinum complexes; Cross linking between DNA bases; Di region theory; Mechanism of carcinogenesis; Minoplatin; Predictive design of anticancer agent; Second generation anticancer agent; Selectivity of anticancer agent

Indexed keywords

ALKYLATION; CHEMOTHERAPY; CROSSLINKING; DNA; MUTAGENESIS; SYNTHESIS (CHEMICAL);

ANTICANCER AGENT; ANTICANCER PLATINUM COMPLEXES; CARCINOGENESIS MECHANISM; CLINICAL TESTING; DI REGION THEORY; GENETIC TOXICITY; MINOPLATIN; PREDICTIVE DESIGN; SECOND GENERATION ANTICANCER AGENT;

CARCINOGENS;

EID: 33645755886     PISSN: 10069291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11426-004-0048-4     Document Type: Article

References (32)

1. Dai, Q. H., Research on mechanism of chemical carcinogenesis and quantitative structure-carcinogenic activity relationship, di-region theory - A quantitative molecular orbital model of carcinogenic activity for polycyclic aromatic hydrocarbons, Scientia Sinica, 1980, 23(4): 453.
2. Dai, Q. H., Di-region theory: New discovery on mechanism of carcinogenesis, Mol. Eng. 1998, 1: 69-81.
3. Dai, Q. H., Di-region Theory: Mechanism of Carcinogenesis and Non-empirical Quantitative Structure-biological Activity Relationship of Carcinogens (in Chinese), Beijing: Science Press, 2000.
4. Dai, Q. H., Mechanism of carcinogenesis revealed through the theoretical treatment on structure-carcinogenic activity relationship of polycyclic aromatic hydrocarbons, in Polynuclear Aromatic Hydrocarbons: Synthesis, Properties, Analytical Measurement, Occurrence and Biological Effects (eds. Garrigues, P. and Lamotte, M.), Switzerland: Gordon and Breach Science Publishers, 1991, 247-258.
5. Dai, Q. H., Di-region theory - New conception for quantitative structure-carcinogenic activity relationship and mechanism of chemical carcinogenesis, in Polynuclear Aromatic Hydrocarbons: Mechanisms, Methods and Metabolism (eds. Cooke, M. and Dennis, A.), Ohio: Battelle Press, Columbus, 1984, 1045-1073.
6. Dai, Q. H., Chen, S., Li, Y. X., Carcinogenesis of asbestos switched on by inducing cross-linkage between DNA complementary pair bases, Chinese Science Bulletin, 2002, 47(13): 1086-1091.
7. Dai, Q. H., Liu, X., DNA interstrand cross-link induced by estrogens as well as their complete and synergic carcinogenesis, Chinese Science Bulletin, 2000, 45(23): 2125-2129.
8. Dai, Q. H., Lu, P., Peng, S. H., Zhang, Q. R., Carcinogenesis switched on by DNA cross-link between complementary bases aroused by aflatoxin and N-nitroso compounds, Progress in Natural Science, 2003, 13(8): 561-567.
9. Rawley, J. D., A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining, Nature, 1973, 243: 290-293.
10. Sandberg, A. A., Chen, Z., Cytogenetics of cancer: cancer cytogenetics: Nomenclature and clinical applications, in Molecular Biology in Cancer Medicine (eds. Kurzrock, R. and Talpaz, M.), London: Martin Dunitz, 1995, 55-84.
11. Skalka, A. M., Goff, S. P. (eds.), Reverse Transcriptase, New York: Gold Spring Harbor Laboratory Press, 1993.
12. Dai, Q. H., Di-region theory for carcinogenesis and wholesale molecular orbital calculation - An example of revealing an unknown biochemical process through quantum chemical calculation, J. Mol. Structure (TheoChem), 1987, 149(1/2): 167-168.
13. Dai, Q. H., Di-region theory, mechanism of carcinogenesis uncovered by theoretical treatment of a quantitative structure-biological activity relationship, in Recent Advances of Chemistry and Molecular Biology in Cancer Research, (eds. Dai, Q. H., Armour, M. A. and Zheng, Q. Y), Beijing/Heidelberg: Science Press/Springer-Verlag, 1993, 29-47.
14. Dai, Q. H., Xu, P. R., Xiao, P., Shi, B. Z., Synthesis of anticancer platinum complexes based upon di-region theory, J. of Beijing Polytechnic University (Beijing Gongye Daxue Xuebao), 1985, 11(2): 145-147.
15. Zwelling, L. A., Kohn, K. W., Platinum complexes, in Pharmacologic Principles of Cancer Treatment (ed. Chabner, B.), Philadelphia: Saunders Company, 1982, 309-339.
16. Dai, Q. H.(inventor), Cis-platinum-diammine complexes and antitumorous compositions, US patent 5,198,564; British patent 2,209,161; Chinese patent ZL 87 104027.1.
17. Dai, Q. H., Some research on new synthesis of chloramphenicol, Scientia (in Chinese only, cf. CA 8862114r), 1977, (9): 381-389.
18. Natile, G, Mauro, C., Antitumor active trans-platinum compounds, in Metal Ions in Biological Systems, Vol. 42, Metal Complexes in Tumor Diagnosis and As Anticancer Agents (eds. Sigel, A. and Sigel, H.), New York: Marcel Dekker, Inc., 2004, 209-250.
19. Farrell, N., Polynuclear platinum drugs, in Metal Ions in Biological Systems, Vol. 42, Metal Complexes in Tumor Diagnosis and As Anticancer Agents (eds. Sigel, A. and Sigel, H.), New York: Marcel Dekker, Inc., 2004, 251-296.
20. O'Dwyer, P. J., Stevenson, J. P., Johnson, S. W., Clinic experience: DACH-based platinum drugs, in Platinum-based Drugs in Cancer Therapy (eds. Kelland, L. R., Farrell, N. P.), Totowa: Humana Press, 2000, 231-249.
21. Allegra, C. J., Oxaliplatin in the treatment of patients with advanced colorectal cancer, in Progress in Oncology 2001 (eds. DeVita, Jr., V. C., Hellman, S., Rosenberg, S. A.), Sudbury: Jones and Bartlett Publishers, 2001, 159.
22. Lenz, G., Hacker, U. T., Kern, W. et al, Adverse reaction to oxaliplatin: A retrospective study of 25 patients treated on one institution, Anti-Cancer Drugs, 2003, 14(9): 731-733.
23. Sarrio, R. G., Munoz, E. C., Urtasun, J. A. et al., The addition of oxaliplatin to the Mayo clinic schedule significantly increase its toxicity: A retrospective analysis of patient with advanced colorectal cancer, Revista de Oncologia (in English, cf. CA 139 111249w), 2003, 5(2): 88-92.
24. Cleare, M. J., Hydes, P. C., Malerbi, R. W. et al., Anti-tumor platinum complexes: Relationships between chemical properties and activity, Biochimie, 1978, 60: 835-850.
25. Highley, M. S., Calvert, A. H., Clinical experience with cisplatin and carboplatinm, in Platinum-based Drugs in Cancer Therapy (eds. Kelland, L. R., Farrell, N. P.), Totowa: Humana Press, 2000, 171-194.
26. Kelland, L. R., New platinum drugs, in Platinum-based Drugs in Cancer Therapy (eds. Kelland, L. R., Farrell, N. P.), Totowa: Humana Press, 2000, 300.
27. Kato, H., Fukuchi, M., Manda, R. et al., Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas, Anticancer Research, 2003, 23(4): 3493-3498.
28. Cremer, D., Ab initlo calculation of the equilibrium structure of cyclobutane, J. Am. Chem. Soc., 1977, 99: 1307.
29. Neidle, S., Ismail, I. M, Sadler, P. J., The structure of the antitumor complex cis-(diammino)-(1,1-cyclobutanedicarboxylato) Pt(II): X ray and nmr studies, J. Inorganic Biochemistry, 1980, 13: 205-212.
30. Bauman, L. E., Laane, J., Pseudorotation of cyclopentane and its deuterated derivatives, J. Phys. Chem., 1988, 92: 1040.
31. Dai, Q. H., Zheng, Q. Y, Zhou, Q. L.(inventors), Cis-diammine-1,1-cyclopentanodi-carboxylatoplatinum (II) with anticancer activity, Chinese patent ZL 94 1 17561.8, 1998-08-29.
32. Feng, J. C., Tang, W. X., Ji, X. J. et al, Synthesis, characterization and antitumorigenic activity of carboplatin analogous, Chinese Journal of Applied Chemistry (in Chinese), 1989, 6(3): 10-14.